Citations

Showing 10 of 108104 citations.

Risk of pneumonia in asthmatic children using inhaled corticosteroids: a nested case-control study in a birth cohort
Shrestha, Pragya , Ryu, Euijung , Kwon, Jung Hyun , Sohn, Sunghwan , Park, Miguel , Juhn, Young J. , King, Katherine S. , Juhn, Y J , Wi, Chung‐Il , Liu, Hongfang , Kwon, Jung Hyun

Mayo Clinic

BMJ Open | March 10, 2022 | Volume: 12 | Issue: 3 | Pages: e051926

10.1136/bmjopen-2021-051926 | PMID 35273042 Get It

Background Inhaled corticosteroids (ICSs) are important in asthma management, but there are concerns regarding associated risk of pneumonia. While studies in asthmatic adults have shown inconsistent results, this risk in asthmatic children is unclear. Objective Our aim was to determine the association of ICS use with pneumonia risk in asthmatic children. Methods A nested case-control study was performed in the Mayo Clinic Birth Cohort. Asthmatic children (<18 years) with a physician diagnosis of asthma were identified from electronic medical records of children born at Mayo Clinic from 1997 to 2016 and followed until 31 December 2017. Pneumonia cases defined by Infectious Disease Society of America were 1:1 matched with controls without pneumonia by age, sex and asthma index date. Exposure was defined as ICS prescription at least 90 days prior to pneumonia. Associations of ICS use, type and dose (low, medium and high) with pneumonia risk were analysed using conditional logistic regression. Results Of the 2108 asthmatic children eligible for the study (70% mild intermittent and 30% persistent asthma), 312 children developed pneumonia during the study period. ICS use overall was not associated with risk of pneumonia (adjusted OR: 0.94, 95% CI: 0.62 to 1.41). Poorly controlled asthma was significantly associated with the risk of pneumonia (OR: 2.03, 95% CI: 1.35 to 3.05; p<0.001). No ICS type or dose was associated with risk of pneumonia. Conclusion ICS use in asthmatic children was not associated with risk of pneumonia but poorly controlled asthma was. Future asthma studies may need to include pneumonia as a potential outcome of asthma management.
Optogenetic Control of Engrafted Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Live Mice: A Proof-of-Concept Study
Joshi, Jyotsna, Xu, Bing , Rubart, Michael , Bao, Xiaoping , Chaliki, Hari P. , Scott, Luis R. , Zhu, Wuqiang , Bao, Xiaoping , Zhu, Wuqiang , Rubart, Michael , Chang, Yun

Mayo Clinic

Cells | March 10, 2022 | Volume: 11 | Issue: 6 | Pages: 951

10.3390/cells11060951 | PMID 35326403 Get It

Background: Cellular transplantation has emerged as promising approach for treating cardiac diseases. However, a poor engraftment rate limits our understanding on how transplanted cardiomyocytes contribute to cardiac function in the recipient’s heart. Methods: The CRISPR/Cas9 technique was employed for stable and constitutive gene expression in human-induced pluripotent stem-cell-derived cardiomyocytes (hiPSC-CMs). Myocardial infarction was induced in adult immunodeficient mice, followed by intramyocardial injection of hiPSC-CMs expressing either CCND2/channelrhodopsin 2 (hiPSC-CCND2OE/ChR2OECMs) or CCND2/luciferase (hiPSC-CCND2OE/LuciOECMs). Six months later, hemodynamics and intramural electrocardiogram were recorded upon blue light illuminations in anesthetized, open-chest mice. Results: Blue light resets automaticity of spontaneously beating hiPSC-CCND2OE/ChR2OECMs in culture, but not that of hiPSC-CCND2OE/LuciOECMs. Response to blue light was also observed in mice carrying large (>106 cells) intracardiac grafts of hiPSC-CCND2OE/ChR2OECM but not in mice carrying hiPSC-CCND2OE/LuciOECMs. The former exhibited single premature ventricular contractions upon light illumination or ventricular quadrigeminy upon second-long illuminations. At the onset of premature ventricular contractions, maximal systolic ventricular pressure decreased while ventricular volume rose concomitantly. Light-induced changes reversed upon resumption of sinus rhythm. Conclusions: We established an in vivo model for optogenetic-based modulation of the excitability of donor cardiomyocytes in a functional, reversible, and localized manner. This approach holds unique value for studying electromechanical coupling and molecular interactions between donor cardiomyocytes and recipient hearts in live animals.
Orofacial Muscle Strength across the Dysarthrias
Clark, Heather M. , Duffy, Joseph R. , Hanley, Holly , Solomon, Nancy Pearl , Strand, Edythe A. , Hanley, Holly , Solomon, Nancy Pearl , Clark, Heather M , Duffy, Joseph R

Mayo Clinic

Brain Sciences | March 10, 2022 | Volume: 12 | Issue: 3 | Pages: 365

10.3390/brainsci12030365 | PMID 35326321 Get It

This study compared orofacial muscle strength between normal and dysarthric speakers and across types of dysarthria, and examined correlations between strength and dysarthria severity. Participants included 79 speakers with flaccid, spastic, mixed spastic–flaccid, ataxic, or hypokinetic dysarthria and 33 healthy controls. Maximum pressure generation (Pmax) by the tongue, lips, and cheeks represented strength. Pmax was lower for speakers with mixed spastic–flaccid dysarthria for all tongue and lip measures, as well as for speakers with flaccid or spastic dysarthria for anterior tongue elevation and lip compression. Anterior tongue elevation and cheek compression tended to be lower than normal for the hypokinetic group. Pmax did not differ significantly between controls and speakers with ataxic dysarthria on any measure. Correlations were generally weak between dysarthria severity and orofacial weakness but were stronger in the dysarthria groups with more prominent orofacial weakness. The results generally support predictions that orofacial weakness accompanies flaccid and/or spastic dysarthria but not ataxic dysarthria. The findings support including type of dysarthria as a variable of interest when examining orofacial weakness in motor speech disorders.
New therapeutics for primary hyperoxaluria type 1
Dejban, Pegah, Lieske, John C., Dejban, Pegah, Lieske, John C.

Mayo Clinic

Current Opinion in Nephrology & Hypertension | March 10, 2022 | Volume: 31 | Issue: 4 | Pages: 344-350

10.1097/mnh.0000000000000790 | PMID 35266883 Get It

Purpose of review Primary hyperoxaluria type 1 (PH1) is a rare genetic disorder that causes hepatic overproduction of oxalate and, often, nephrocalcinosis, nephrolithiasis, chronic kidney disease, and kidney failure. The purpose of the review is to provide an update on current emerging therapies for the treatment of PH1. Recent findings Use of ribonucleic acid interference (RNAi) therapeutics that target the liver to block production of key enzymes along pathways that generate oxalate is a promising approach. Available evidence supports the efficacy of both Lumasiran (targeting glycolate oxidase) and Nedosiran (targeting hepatic lactate dehydrogenase (LDHa)) to reduce urinary oxalate excretion in PH1. The efficacy of alternative approaches including stiripentol (an anticonvulsant drug that also targets LDHa), lanthanum (a potential gastrointestinal oxalate binder), and Oxalobacter formigenes (a bacterium that can degrade oxalate within the gastrointestinal tract and may also increase its secretion from blood) are all also under study. Genetic editing tools including clustered regularly interspaced short palindromic repeats/Cas9 are also in preclinical study as a potential PH1 therapeutic. Summary Novel treatments can reduce the plasma oxalate concentration and urinary oxalate excretion in PH1 patients. Thus, it is possible these approaches will reduce the need for combined kidney and liver transplantation to significantly decrease the morbidity and mortality of affected patients.
Large-scale Integrated Analysis of Genetics and Metabolomic Data Reveals Potential Links Between Lipids and Colorectal Cancer Risk
Shu, Xiao-Ou , Chen, Zhishan, Long, Jirong, Guo, Xingyi, Yang, Yaohua , Qu, Conghui, Ahn, Yoon-Ok, Cai, Qiuyin , Casey, Graham, Gruber, Stephen B. , Huyghe, Jeroen R. , Jee, Sun Ha, Jenkins, Mark A., Jia, Wei-Hua, Jung, Keum Ji, Kamatani, Yoichiro, Kim, Dong-Hyun, Marchand, Loic Le, Newcomb, Polly A., Oh, Jae Hwan, Ose, Jennifer , Pai, Rish K. , Pan, Zhi-Zhong, Ren, Ze-Fang, Shin, Aesun, Sun, Xiaohui, Tangen, Catherine M., Tanikawa, Chizu, Duijnhoven, Fränzel J.B. van , Guelpen, Bethany Van , Woods, Michael O. , Wu, Anna H., Peters, Ulrike , Jee, Sun Ha , Chen, Zhishan , Shu, Xiao-Ou , Kim, Jeongseon , Kweon, Sun-Seog , Matsuda, Koichi , Matsuo, Keitaro , Ose, Jennifer , Oze, Isao , Pai, R K , Pharoah, Paul D P , Playdon, Mary C , Schoen, Robert E , Shin, Min‐Ho , Shu, Xiao-Ou , Ulrich, Cornelia M , van Duijnhoven, Fränzel J B , Van Guelpen, Bethany , Wolk, Alicja , Woods, Michael O , Peters, Ulrike , Zheng, Wei , Gruber, Stephen B , Cai, Qiuyin , Chen, Zhishan, Long, Jirong, Guo, Xingyi, Yang, Yaohua , Qu, Conghui, Ahn, Yoon-Ok, Casey, Graham, Huyghe, Jeroen R , Jenkins, Mark A., Jia, Wei-Hua, Jung, Keum Ji, Kamatani, Yoichiro, Kim, Dong-Hyun, Marchand, Loic Le, Newcomb, Polly A., Oh, Jae Hwan, Pan, Zhi-Zhong, Ren, Ze-Fang, Shin, Aesun, Sun, Xiaohui, Tangen, Catherine M., Tanikawa, Chizu, Wu, Anna H.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | March 10, 2022 | Volume: 31 | Issue: 6 | Pages: 1216-1226

10.1158/1055-9965.epi-21-1008 | PMID 35266989 Get It

Abstract Background: The etiology of colorectal cancer is not fully understood. Methods: Using genetic variants and metabolomics data including 217 metabolites from the Framingham Heart Study (n = 1,357), we built genetic prediction models for circulating metabolites. Models with prediction R2 &gt; 0.01 (Nmetabolite = 58) were applied to predict levels of metabolites in two large consortia with a combined sample size of approximately 46,300 cases and 59,200 controls of European and approximately 21,700 cases and 47,400 controls of East Asian (EA) descent. Genetically predicted levels of metabolites were evaluated for their associations with colorectal cancer risk in logistic regressions within each racial group, after which the results were combined by meta-analysis. Results: Of the 58 metabolites tested, 24 metabolites were significantly associated with colorectal cancer risk [Benjamini–Hochberg FDR (BH-FDR) &lt; 0.05] in the European population (ORs ranged from 0.91 to 1.06; P values ranged from 0.02 to 6.4 × 10−8). Twenty one of the 24 associations were replicated in the EA population (ORs ranged from 0.26 to 1.69, BH-FDR &lt; 0.05). In addition, the genetically predicted levels of C16:0 cholesteryl ester was significantly associated with colorectal cancer risk in the EA population only (OREA: 1.94, 95% CI, 1.60−2.36, P = 2.6 × 10−11; OREUR: 1.01, 95% CI, 0.99−1.04, P = 0.3). Nineteen of the 25 metabolites were glycerophospholipids and triacylglycerols (TAG). Eighteen associations exhibited significant heterogeneity between the two racial groups (PEUR-EA-Het &lt; 0.005), which were more strongly associated in the EA population. This integrative study suggested a potential role of lipids, especially certain glycerophospholipids and TAGs, in the etiology of colorectal cancer. Conclusions: This study identified potential novel risk biomarkers for colorectal cancer by integrating genetics and circulating metabolomics data. Impact: The identified metabolites could be developed into new tools for risk assessment of colorectal cancer in both European and EA populations.
Enhancing Diagnostics in Orthopedic Infections
Higgins, Eibhlin , Suh, Gina A. , Tande, Aaron J. , Tande, Aaron , Suh, Gina A

Mayo Clinic

Journal of Clinical Microbiology | March 10, 2022 | Volume: 60 | Issue: 6 | Pages: No page available

10.1128/jcm.02196-21 | PMID 35264020 Get It

Accurate diagnosis of orthopedic infection is crucial in guiding both antimicrobial therapy and surgical management in order to optimize patient outcomes. A variety of microbiological and nonmicrobiological methods are used to establish the presence of a musculoskeletal infection. In this minireview, we examine traditional culture-based and newer molecular methodologies for pathogen detection, as well as systemic and localized assays to assess host response to maximize diagnostic yield.
Treatment of Ruptured and Nonruptured Aneurysms Using a Semisolid Iodinated Embolic Agent (Adv. Mater. 10/2022)
Albadawi, Hassan , Fowl, Richard J., Chong, Brian W. , Mayer, Joseph L. , Öklü, Rahmi , Oklu, Rahmi , Zhang, Zefu , Altun, İzzet , Salomao, Marcela , Jahanyar, Jama

Mayo Clinic

Advanced Materials | March 10, 2022 | Volume: 34 | Issue: 10 | Pages: No page available

10.1002/adma.202270081 Get It

The role of SARS‐CoV‐2 infection and its vaccines in various types of hair loss
Hatami, Parvaneh , Afshar, Zeinab Mohseni , Aghazadeh, Nessa , Hatami, Parvaneh , Aghazadeh Mohandesi, Nessa , Aryanian, Zeinab , Balighi, Kamran , Afshar, Zeinab Mohseni

Mayo Clinic

Dermatologic Therapy | March 10, 2022 | Volume: 35 | Issue: 6 | Pages: No page available

10.1111/dth.15433 | PMID 35266262 Get It

Rbbp4 loss disrupts neural progenitor cell cycle regulation independent of Rb and leads to Tp53 acetylation and apoptosis
Schultz‐Rogers, Laura , Thayer, Michelle L. , Kambakam, Sekhar , Wierson, Wesley A. , Helmer, Jordan A., Wishman, Mark , Wall, Kristen A., Greig, Jessica L., Forsman, Jaimie L., Puchhalapalli, Kavya, Nair, Siddharth, Luiken, Jon M., Blackburn, Patrick R. , Kool, Marcel , McGrail, Maura , McGrail, Maura , Thayer, Michelle L., Wall, Kristen A., Weiss, Trevor J. , Luiken, Jon M. , Ekker, Stephen C.

Mayo Clinic

Developmental Dynamics | March 10, 2022 | Volume: 251 | Issue: 8 | Pages: 1267-1290

10.1002/dvdy.467 | PMID 35266256 Get It

AbstractBackgroundRetinoblastoma binding protein 4 (Rbbp4) is a component of transcription regulatory complexes that control cell cycle gene expression. Previous work indicated that Rbbp4 cooperates with the Rb tumor suppressor to block cell cycle entry. Here, we use genetic analysis to examine the interactions of Rbbp4, Rb, and Tp53 in zebrafish neural progenitor cell cycle regulation and survival.ResultsRbbp4 is upregulated across the spectrum of human embryonal and glial brain cancers. Transgenic rescue of rbbp4 mutant embryos shows Rbbp4 is essential for zebrafish neurogenesis. Rbbp4 loss leads to apoptosis and γ‐H2AX in the developing brain that is suppressed by tp53 knockdown or maternal zygotic deletion. Mutant retinal neural precursors accumulate in M phase and fail to initiate G0 gene expression. rbbp4; rb1 mutants show an additive effect on the number of M phase cells. In rbbp4 mutants, Tp53 acetylation is detected; however, Rbbp4 overexpression did not rescue DNA damage‐induced apoptosis.ConclusionRbbp4 is necessary for neural progenitor cell cycle progression and initiation of G0 independent of Rb. Tp53‐dependent apoptosis in the absence of Rbpb4 correlates with Tp53 acetylation. Together these results suggest that Rbbp4 is required for cell cycle exit and contributes to neural progenitor survival through the regulation of Tp53 acetylation.
Thank You for a Successful 2021!
Sittig, Dean F. , Petersen, Carolyn , Downs, Stephen M. , Lehmann, Jenna S. , Sittig, Dean F , Petersen, Carolyn , Lehmann, Christoph U.

Mayo Clinic

Applied Clinical Informatics | March 10, 2022 | Volume: 13 | Issue: 01 | Pages: 304-314

10.1055/s-0042-1744385 | PMID 35263801 Get It